Paracentesis is Associated with Reduced Mortality in Patients Hospitalized with Cirrhosis and Ascites by Orman, Eric S. et al.
Paracentesis is Associated with Reduced Mortality in Patients 
Hospitalized with Cirrhosis and Ascites
Eric S. Orman, MD, MSCR1,2, Paul H. Hayashi, MD, MPH1, Ramon Bataller, MD, PhD1,3, and 
A. Sidney Barritt IV, MD, MSCR1
1Division of Gastroenterology and Hepatology, Department of Medicine, University of North 
Carolina, Chapel Hill
2Division of Gastroenterology and Hepatology, Department of Medicine, Indiana University 
School of Medicine
3Department of Nutrition, University of North Carolina, Chapel Hill
Abstract
Background & Aims—Diagnostic paracentesis is recommended for patients with cirrhosis 
admitted to the hospital for ascites or encephalopathy. However, it is not known if clinicians in the 
United States adhere to this recommendation; a relationship between paracentesis and clinical 
outcome has not been reported. We analyzed a US database to determine the frequency of 
paracentesis and its association with mortality.
Methods—The 2009 Nationwide Inpatient Sample (which contains data from approximately 8 
million hospital discharges each year) was used to identify patients with cirrhosis and ascites 
admitted with a primary diagnosis of ascites or encephalopathy. In-hospital mortality, length of 
stay, and hospital charges were compared for those who did and did not undergo paracentesis. 
Outcomes were compared for those who received an early paracentesis (within 1 day of 
admission) and those who received one later.
Results—Of 17,711 eligible admissions, only 61% underwent paracentesis. In-hospital mortality 
was reduced by 24% among patients who underwent paracentesis (6.5% vs 8.5%, adjusted odds 
ratio [OR], 0.55; 95% confidence interval [CI], 0.41–0.74). Most paracenteses (66%) occurred ≤1 
day after admission. In-hospital mortality was lower among patients who received early 
paracentesis than those who received it later (5.7% vs 8.1%; P=.049), although this difference was 
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not significant after adjustment for confounders (OR, 1.26; 95% CI, 0.78–2.02). Among patients 
who underwent paracentesis, the mean hospital stay was 14% longer, and hospital charges were 
29% greater than for patients that did not receive the procedure.
Conclusions—Paracentesis is underused for patients admitted to the hospital with ascites; the 
procedure is associated with increased short-term survival. These data support practice guidelines 
derived from expert opinion. Studies are needed to identify barriers to guideline adherence.
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Peritonitis; Quality of Health Care; Health Services; NIS Analysis; Liver Fibrosis
INTRODUCTION
Ascites is the most common complication of cirrhosis,1 and its development is associated 
with substantially increased mortality.2 One of the most feared complications of ascites is 
spontaneous bacterial peritonitis (SBP), which occurs in 25% of patients and is fatal in 
30%.3, 4 SBP is present in 10–30% of all hospitalized patients with ascites,5 and the risk of 
complications from diagnostic paracentesis is negligible.6, 7 Therefore, for more than a 
decade experts have recommended that a diagnostic paracentesis be performed to exclude 
SBP in all patients with ascites admitted to the hospital.5, 8, 9
Recently, a set of quality indicators was developed for the care of patients with cirrhosis, 
and a diagnostic paracentesis in patients admitted to the hospital for symptoms from ascites 
or encephalopathy was identified as one of the most important indicators of quality.10 
Despite practice guideline recommendations and its selection as a quality indicator, 
diagnostic paracentesis is done in less than 60% of indicated cases within the Veteran 
Affairs health system.11 However, this low adherence has not been described in a broader 
population. Furthermore, despite the strong evidence supporting specific interventions for 
SBP (e.g., antibiotics and albumin) in improving patient outcomes,12, 13 data linking the 
widespread use of paracentesis with clinical outcomes are lacking, and diagnostic 
paracentesis is rated as a “Level C” quality indicator (based on expert opinion or case 
series).10 Demonstrating improved outcomes with early paracentesis in a large hospitalized 
population may help increase the uptake of current recommendations in the community.
We therefore sought to estimate the frequency of paracentesis in a nationally representative 
sample of patients with cirrhosis hospitalized for ascites or hepatic encephalopathy and to 
evaluate the association between paracentesis and mortality, length of stay, and hospital 
charges. Among those who did receive a paracentesis, we also examined the relationship 
between delayed paracentesis and mortality.
METHODS
Data Source
We utilized data from the 2009 Nationwide Inpatient Sample (NIS), the largest all-payer 
database of hospital discharges in the US, totaling approximately 8 million discharges 
yearly. It is a component of the Healthcare Cost and Utilization Project, sponsored by the 
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Agency for Healthcare Research and Quality.14 The NIS represents a 20% sample of non-
federal acute care hospitals in the US and is stratified on hospital ownership/control, size, 
teaching status, location, and region. The sampling design supports national estimates of 
study findings. Each record represents a single patient discharge and contains demographic 
information, up to 25 diagnoses and 15 procedures, admission type, patient disposition, 
length of stay, hospital charges, and hospital characteristics.
Study Sample
We used International Classification of Diseases, Ninth Revision, Clinical Modification 
(ICD-9-CM) codes to identify all patients ≥ 18 years old with a primary discharge diagnosis 
of ascites (789.59) or SBP (567.23). We also included patients with a primary diagnosis of 
hepatic encephalopathy (ICD-9-CM 572.2) if they had a secondary diagnosis of ascites. We 
required that all patients have a secondary diagnosis of cirrhosis (ICD-9-CM 571.2, 571.5, 
571.6). The first listed diagnosis was considered the primary diagnosis, and additional 
diagnoses were considered secondary. The study sample was chosen to resemble the 
denominator for the associated quality indicator (those “admitted to the hospital for 
evaluation and management of symptoms related to ascites or encephalopathy”).10 We 
repeated the main analyses for patients with any (primary or secondary) diagnoses of ascites 
and/or SBP. We excluded patients transferred from another health facility to avoid 
misclassifying patients who had received a paracentesis prior to transfer. The codes used to 
define the sample were previously validated.11, 15, 16
Variables
Our primary factor of interest was the performance of a paracentesis as determined with a 
validated definition (ICD-9-CM 54.91).17 In the subgroup who received a paracentesis, we 
examined early versus delayed paracentesis (≤ 1 day versus > 1 day after admission). We 
considered patient age, sex, race/ethnicity (white, black, Hispanic, or other), weekday versus 
weekend admission, elective versus non-elective admission, primary health insurance payer 
(Medicare, Medicaid, private insurance, self-pay, or other), median household income 
quartile for the patient’s home zip code, and comorbidities measured by the Elixhauser 
comorbidity index (excluding the “liver disease” comorbidity).18, 19 Age was specified 
categorically (< 55, 55–64, or ≥ 65) in models because the relationship between age and 
paracentesis was non-linear. Additionally, we examined diagnoses of sepsis (ICD-9-CM 
038, 020.2, 790.7, 117.9, 112.5, 112.81) and acute renal failure (584.5, 584.6, 584.7, 584.8, 
584.9) using validated definitions.20, 21 We examined hospital factors including size (small, 
medium, or large), ownership/control (non-federal government, non-profit private, or 
investor-owned private), US region (Northeast, Midwest, South, or West), teaching status, 
and location (rural versus urban). Race/ethnicity was missing in 10% of observations, and 
9% were missing time-to-paracentesis; no other variable was missing in more than 3%. 
Missing data were handled using listwise deletion; analyses were repeated after assigning all 
observations with missing time-to-paracentesis to both the early and delayed groups.
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Outcomes
The primary outcome was in-hospital mortality. Secondary outcomes were hospital length of 
stay (days) and total hospital charges (US dollars).
Statistical Analysis
Categorical variables were compared with Pearson’s χ2 test, and continuous variables were 
compared with Student’s t-test. Factors associated with paracentesis performance were 
assessed using multivariate logistic regression. Logistic regression was also used to evaluate 
the association between paracentesis and mortality. To account for potential selection bias of 
moribund patients in whom paracentesis may be deemed futile, the relationship between 
paracentesis and mortality was also examined after excluding those who died on the day of 
admission. Within the subgroup who received a paracentesis, additional logistic models 
examined the relationship between delayed paracentesis and mortality, and factors 
associated with delayed paracentesis. Poisson regression was used to examine the 
relationship between paracentesis and length of stay. The relationship between paracentesis 
and hospital charges was modeled using linear regression with logarithmic transformation of 
charges. Coefficients were exponentiated to determine the percentage change in charges 
associated with paracentesis. All multivariate models included age, sex, race/ethnicity, 
weekend and elective admission, primary payer, median zip code income, comorbidities, 
sepsis, acute renal failure, hospital size, ownership/control, region, teaching status, and 
location. In mortality models, interaction terms for age, sex, weekend and elective 
admission, comorbidities, acute renal failure, and sepsis were assessed but were not 
statistically significant, and were not included in the final models.
Analyses were performed using Stata version 12.1 (StataCorp LP, College Station, TX). All 
analyses accounted for the stratified cluster sampling design and incorporated discharge-
level weights to produce national estimates with 95% confidence intervals (CI). All p-values 
were based on 2-sided tests, and were considered statistically significant when p < 0.05. The 
University of North Carolina Institutional Review Board approved this study.
RESULTS
Study Sample Characteristics and Paracentesis
Of the nearly 40 million national discharges in 2009, 17,711 met inclusion criteria and were 
included in the analysis. 10,500 had a primary diagnosis of hepatic encephalopathy, 2,977 
had a primary diagnosis of ascites, and 4,233 had a primary diagnosis of SBP. Overall, 
10,743 patients (60.7%; 95% CI, 58.6–62.7%) had a paracentesis during the hospitalization. 
Paracentesis was performed in 3,262 patients with a primary diagnosis of SBP (77.1%; 95% 
CI, 74.0–80.1%), compared to 7,481 of those with a primary diagnosis of encephalopathy or 
ascites (55.5%; 95% CI, 53.3–57.7%) (Supplementary Table). Only 50.9% of patients with 
any diagnosis of ascites had a paracentesis. The mean age was 58.2 years, 63.7% were male, 
and 66.5% were Caucasian. Patient demographics stratified by the receipt of a paracentesis 
are shown in Table 1. Those who received a paracentesis were slightly younger, had a higher 
median income in their home zip code, were more likely to have concurrent sepsis or acute 
renal failure, were less likely to be in the South region, and were more likely to be in a 
Orman et al. Page 4
Clin Gastroenterol Hepatol. Author manuscript; available in PMC 2015 March 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
teaching or urban hospital. Paracentesis performance ranged from 56.4% in the South to 
64.1% in the Northeast. Sex, race/ethnicity, admission circumstances, primary payer status, 
comorbidities, hospital size, and ownership did not differ between the two groups. In 
multivariate analysis, paracentesis was independently associated with self-pay (compared to 
private insurance) (odds ratio [OR] 1.41; 95% CI, 1.02–1.96), sepsis (OR 1.43; 95% CI, 
1.02–2.00), acute renal failure (OR 1.53; 95% CI, 1.29–1.81), and hospital teaching status 
(OR 1.32; 95% CI, 1.08–1.61). In contrast, paracentesis was less likely to occur in those 
admitted on the weekend (OR 0.84; 95% CI, 0.71–1.00) and those in the South region (OR 
0.76; 95% CI 0.57–1.00).
Paracentesis and In-Hospital Mortality
Patients who received a paracentesis had lower in-hospital mortality than those who did not 
get a paracentesis (6.5% versus 8.5%, p = 0.03). The results of bivariate and multivariate 
mortality analyses are shown in Table 2. The mean age of those who died (59.7) was slightly 
higher than that of those who lived to discharge (58.1). Those who died had more 
comorbidities (mean 4.0) than those who lived (3.6). Mortality was greater in those with 
sepsis (27.2% versus 5.7%) and in those with acute renal failure (16.4% versus 4.0%). In-
hospital mortality was lower in the Midwest (4.6%) than in the other regions (7.9%). 
Bivariate analyses of other factors showed no differences in in-hospital mortality. The 
performance of paracentesis was associated with decreased in-hospital mortality in 
multivariate analysis (OR 0.55; 95% CI, 0.41–0.74). This mortality benefit was seen 
exclusively for those with a primary diagnosis of encephalopathy or ascites (6.8% versus 
9.1%, adjusted OR 0.54; 95% CI, 0.38–0.76) and not for those with a primary diagnosis of 
SBP (5.8% versus 4.7%, adjusted OR 0.91; 95% CI, 0.38–2.19) (Supplementary Table). 
After excluding the 2.3% of in-hospital deaths that occurred on the day of admission, 
paracentesis remained associated with reduced mortality in multivariate analysis (OR 0.59; 
95% CI, 0.43–0.80). Paracentesis was also associated with reduced mortality in alternative 
samples that included patients with any diagnosis of ascites or SBP (Supplementary Table).
Delayed Paracentesis
Among those who received a paracentesis, approximately 6,479 (66.0%) received it ≤ 1 day 
after admission. Those who received a delayed paracentesis were slightly older, were more 
likely to be female, were more likely to be admitted on a weekend day, were more likely to 
have Medicare, had more comorbidities, were more likely to have acute renal failure, were 
more likely to be in a private, non-profit hospital, and were less likely to be in a teaching 
hospital (Table 3). Race/ethnicity, elective versus non-elective admission, patient home zip 
code income, concurrent sepsis, hospital size, region, and location (urban/rural) were not 
related to delayed paracentesis in bivariate analyses. In multivariate analysis, delayed 
paracentesis was associated with female sex (OR 1.39; 95% CI, 1.11–1.74), weekend 
admission (OR 1.80; 95% CI, 1.38–2.35), increasing comorbidities (OR 1.16; 95% CI, 1.09–
1.24), and acute renal failure (OR 1.30; 95% CI, 1.06–1.61). Paracentesis was less likely to 
be delayed in teaching hospitals (OR 0.75; 95% CI, 0.57–0.98), and there was regional 
variation, with delay less likely in the South (OR 0.72; 95% CI, 0.53–0.99) and West (OR 
0.61; 95% CI, 0.43–0.85) compared to the Northeast.
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Delayed Paracentesis and In-Hospital Mortality
In-hospital mortality was 5.7% for those whose paracentesis was performed = 1 day after 
admission, compared to 8.1% when paracentesis was delayed (p = 0.049). However, in the 
multivariate model, the association between delayed paracentesis and mortality was not 
statistically significant (OR 1.26; 95% CI, 0.78–2.02). Removing variables that did not 
change the point estimate did not improve precision. Assigning the 9% of patients with 
missing time-to-paracentesis to both the early and delayed groups did not change the results 
(data not shown).
Hospital Length of Stay and Charges
Mean length of stay for those who received a paracentesis was 6.6 days compared to 5.3 
days for those who did not receive a paracentesis (Table 4, p < 0.001). After adjustment in 
the multivariate regression model, those who received a paracentesis had a 14% longer 
length of stay. Likewise, hospital charges were greater for those who had a paracentesis 
($44,586 versus $31,746, p < 0.001), and remained 29% greater in the multivariate model.
DISCUSSION
In this nationally representative sample of hospital admissions, we found that only 61% of 
patients with cirrhosis admitted for ascites or encephalopathy had a paracentesis. When 
paracentesis was performed, only 66% were done ≤ 1 day after admission. Therefore, 
overall only 40% of eligible patients had a timely paracentesis. Paracentesis was associated 
with a significant reduction in mortality but also longer hospital stay and greater expense.
In light of the safety and diagnostic value of paracentesis,5–7 our finding that nearly 40% of 
potentially eligible patients did not receive this care is concerning. The lack of detail in the 
NIS does not allow for firm conclusions on the reasons for underutilization, but potential 
reasons may include a low index of suspicion among providers and a lack of knowledge 
about the high prevalence of SBP, even among asymptomatic patients.5 Alternatively, some 
practitioners may elect to give empiric antibiotics for SBP without performing a 
paracentesis. Providers may overestimate bleeding risk in the setting of thrombocytopenia 
and coagulopathy or lack comfort in performing paracentesis. Survey data from 1996 
indicated that the vast majority of graduating internal medicine residents were comfortable 
performing paracentesis,22 but subsequent changes in resident training and the potential for 
increasing reliance on interventional radiologists could have reduced this confidence. Our 
finding that weekend admissions were associated with delayed paracentesis may reflect 
outsourcing to radiologists during the week. The fact that patients in teaching hospitals were 
more likely to have had a paracentesis likely reflects greater access to hepatologists and 
gastroenterology didactic sessions on cirrhosis care as well as 24/7 coverage by medical 
house staff.
A novel finding of this study is the association between paracentesis and improved survival, 
which to our knowledge has not been previously reported. Kanwal et al. demonstrated a 
reduction in 12-month mortality for patients who received optimum cirrhosis care, including 
paracentesis in hospitalized patients with ascites.11 However, individual quality measures 
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were not reported separately, and the effect was not statistically significant, probably 
because of power limitations. Our findings support current recommendations for 
paracentesis, which have been based largely on expert opinion, and therefore add legitimacy 
to its use as an indicator of quality.10
The mechanism for this beneficial effect cannot be ascertained from the NIS, but is 
presumably related to increased detection and treatment of SBP. Our finding that mortality 
was not altered for those with a primary SBP diagnosis is consistent with this explanation. 
Patients who are diagnosed clinically with SBP without a paracentesis are likely to receive 
appropriate antibiotics and albumin and are therefore likely to have a good outcome. This 
would serve to obscure any direct relationship between paracentesis and survival amongst 
those diagnosed clinically with SBP. The mortality difference for the remaining patients 
diagnosed with ascites or encephalopathy is likely the result of improved SBP diagnosis 
because of the potential for underreporting and under-recognition of SBP. Under-recognition 
of SBP may also explain the lower mortality for the subgroup with an SBP diagnosis 
compared to the subgroup with ascites and encephalopathy diagnoses because the latter 
group likely includes patients with unrecognized and untreated SBP. The lack of sensitivity 
in SBP reporting has been reported elsewhere15 and makes such analyses difficult. In fact, 
this low sensitivity was the rationale for including patients with ascites or encephalopathy in 
the study sample and underscores the need for paracentesis in patients with ascites even 
when SBP is not suspected. Interestingly, patients who received a paracentesis were more 
likely to have concurrent diagnoses of sepsis or acute renal failure. How this finding is 
related to the mortality benefit is unknown, since early diagnosis and treatment of SBP 
would be expected to prevent the development of sepsis and renal failure. It is plausible that 
the presence of renal failure or sepsis on admission would raise the index of suspicion for 
SBP and lower the threshold for providers to perform paracentesis. Alternatively, the 
performance of paracentesis may be a marker of adherence to other evidence-based 
practices, such as albumin for SBP or prophylactic antibiotics for gastrointestinal 
bleeding.13, 23
In contrast to the benefit of paracentesis, delayed paracentesis (compared to early) was not 
associated with increased mortality in multivariate analysis. Although early paracentesis 
leading to diagnosis and treatment of SBP might result in a clinical benefit, patients with 
suspected SBP who receive empiric antibiotics prior to delayed paracentesis may also have a 
good outcome. Such an effect could attenuate the association between delayed paracentesis 
and mortality. Indeed, mortality was reduced for those with prompt paracentesis in bivariate 
analysis.
Length of stay and hospital charges were both increased for patients who received 
paracentesis. How much the 31% higher mortality in the non-paracentesis group contributed 
to shorter stay and less charges is unknown. Some may have had undiagnosed SBP with 
early death and may have otherwise survived with longer hospitalization and increased cost. 
Patients with unrecognized early SBP may have been discharged before the development of 
overt SBP, incurring a shorter length of stay and lower cost during the index hospitalization 
only to be readmitted later. Because the unit of observation is the hospitalization, 
readmissions for complications of previously unrecognized SBP cannot be determined. 
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Indeed, some observations may represent readmissions, potentially contributing to the 
associations with renal failure, sepsis and increased length of stay. The increased costs and 
length of stay could also be related to paracentesis complications such as bleeding or ascites 
leak.
Our study is subject to the limitations of administrative data, including potential 
misclassification of subjects and variables. Where possible, we used previously validated 
codes. In defining the study sample, we used codes for cirrhosis and its complications that 
have been shown to have good specificity.15, 16 Thus our sample likely does reflect an at-
risk group who should undergo paracentesis. In addition, coding for paracentesis had > 80% 
sensitivity in a Canadian study,17 so our estimate of underutilization should be reliable. 
These data do not distinguish between diagnostic and therapeutic paracenteses, procedures 
with different indications and consequences. Our focus was diagnostic paracentesis, and the 
results may be biased since therapeutic procedures could not be excluded. In particular, 
therapeutic paracentesis is more likely to result in complications, which may contribute to 
increased cost and length of stay. Finally, some patients may have insignificant ascites seen 
on imaging only. Such patients may have been misclassified and incorrectly included in this 
study as needing paracentesis. However, such patients would seem uncommon since all had 
a primary or secondary diagnosis of ascites, implying clinically significant fluid.
Missing data may lead to unmeasured confounding and selection biases. The NIS lacks 
detail needed to assess liver disease severity, which impacts both the decision to perform 
paracentesis and mortality. One could argue that severely ill patients may not receive a 
paracentesis because of perceived risks, coagulopathy, or futility. However, patients who 
received a paracentesis were actually more likely to have sepsis or acute renal failure, both 
markers of illness severity. In addition, the benefit of paracentesis persisted after excluding 
deaths on the first hospital day. Kanwal et al. found that patients with worse liver disease are 
more likely to receive recommended ascites care.11 Our findings may therefore 
underestimate the benefit of paracentesis. Finally, because of the retrospective observational 
design of this study, we can determine associations, but cannot conclude causality.
Despite these limitations, this study has strengths that make it an important contribution to 
quality of care in cirrhosis. The NIS is a population-based sample that allows for 
generalizability to all non-federal acute care hospitals in the US. Therefore, it can yield the 
best national estimate of paracentesis utilization compared to other sources. In addition, the 
large sample size allows for analyses of clinical outcomes accounting for multiple 
confounders while maintaining precision.
In conclusion, we found that patients in the US with cirrhosis and ascites hospitalized for 
ascites or encephalopathy often do not receive a paracentesis. These data highlight the large 
gap between current practice and the optimal care of patients with cirrhosis. We also found 
that the performance of paracentesis is associated with improved mortality. These results 
support recommendations that emphasize diagnostic paracentesis as a quality indicator for 
these patients. Future work is needed to identify barriers to diagnostic paracentesis at the 
patient, provider, and system levels, and to implement interventions to increase the 
appropriate use of this procedure to improve patient outcomes.
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Table 1
Characteristics of Cirrhotic Patients Admitted with Ascites, According to the Receipt of a Paracentesis
Paracentesis (n = 10,743) No Paracentesis (n = 6,968) p-valuea
Age in years, mean (95% CI) 57.8 (57.2–58.5) 58.8 (58.1–59.5) 0.03
 < 55, % 43.0 38.5 0.02
 55–64, % 30.4 31.2
 ≥ 65, % 26.6 30.3
Male, % 64.2 62.9 0.44
Race/ethnicity
 White, % 66.2 67.0 0.40
 Black, % 10.0 8.6
 Hispanic, % 17.2 18.8
 Other, % 6.6 5.6
Weekend admission, % 22.0 24.3 0.10
Elective admission, % 7.1 6.4 0.52
Primary payer
 Medicare, % 38.5 43.0 0.06
 Medicaid, % 24.1 21.5
 Private, % 23.8 24.0
 Self-pay, % 9.0 7.0
 Other, % 4.6 4.6
Median zip code income
 1st quartile, % 27.7 31.6 0.03
 2nd quartile, % 26.2 27.5
 3rd quartile, % 25.4 23.3
 4th quartile, % 20.6 17.6
Elixhauser index, mean (95% CI) 3.6 (3.5–3.7) 3.6 (3.5–3.8) 0.43
Sepsis, % 8.7 5.7 0.002
Acute renal failure, % 29.1 21.3 <0.001
Hospital size
 Small, % 9.6 10.4 0.48
 Medium, % 25.0 26.6
 Large, % 65.4 63.0
Ownership/control
 Government, non-federal, % 16.5 16.6 0.12
 Private, non-profit, % 69.5 65.9
 Private, investor-owned, % 14.0 17.5
Hospital region
 Northeast, % 18.9 16.3 0.02
 Midwest, % 19.4 17.9
 South, % 35.6 42.4
 West, % 26.2 23.5
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Paracentesis (n = 10,743) No Paracentesis (n = 6,968) p-valuea
Teaching hospital, % 52.7 43.5 <0.001
Rural (vs. urban) location, % 9.8 13.0 0.01
Abbreviations: CI, confidence interval.
aStudent’s t-test used to compare means; Pearson’s χ2 test used to compare proportions.
Clin Gastroenterol Hepatol. Author manuscript; available in PMC 2015 March 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Orman et al. Page 13
Table 2
Characteristics Associated with In-Hospital Mortality, Bivariate and Multivariate Analyses
Mortality (%) p-valuea Adjusted ORb (95% CI)
Paracentesis
 Yes 6.5 0.03 0.55 (0.41–0.74)
 No 8.5 Ref
Age in years, mean (alive/died) 58.1/59.7 0.05
 < 55 7.0 0.39 Ref
 55–64 6.8 1.01 (0.70–1.45)
 ≥ 65 8.2 1.39 (0.89–2.19)
Sex
 Male 6.9 0.36 Ref
 Female 7.9 1.18 (0.84–1.66)
Race/ethnicity
 White 8.0 0.13 Ref
 Black 4.3 0.54 (0.28–1.04)
 Hispanic 7.2 0.76 (0.50–1.15)
 Other 5.4 0.62 (0.29–1.32)
Admission circumstances
 Weekday 7.3 0.93 Ref
 Weekend 7.3 0.97 (0.70–1.37)
 Non-elective 7.4 0.25 Ref
 Elective 5.4 0.64 (0.33–1.23)
Primary payer
 Private 6.4 0.21 Ref
 Medicare 7.3 0.93 (0.61–1.41)
 Medicaid 6.9 1.34 (0.83–2.15)
 Self-pay 8.9 1.88 (0.97–3.63)
 Other 11.2 2.65 (1.33–5.25)
Median zip code income
 1st quartile 7.4 0.64 Ref
 2nd quartile 8.0 1.01 (0.64–1.60)
 3rd quartile 6.2 0.86 (0.53–1.42)
 4th quartile 7.5 0.78 (0.47–1.30)
Elixhauser index (alive/died) 3.6/4.0 <0.001 1.10 (1.00–1.21)
Sepsis
 Yes 27.2 <0.001 5.94 (3.93–8.98)
 No 5.7 Ref
Acute renal failure
 Yes 16.4 <0.001 4.71 (3.37–6.57)
 No 4.0 Ref
Hospital size
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Mortality (%) p-valuea Adjusted ORb (95% CI)
 Small 7.0 0.62 Ref
 Medium 6.5 1.01 (0.56–1.82)
 Large 7.6 1.12 (0.65–1.90)
Ownership/control
 Government, non-federal 8.2 0.45 Ref
 Private, non-profit 6.8 0.72 (0.44–1.18)
 Private, investor-owned 8.0 0.95 (0.55–1.63)
Hospital region
 Northeast 7.3 0.04 Ref
 Midwest 4.6 0.51 (0.29–0.92)
 South 7.8 0.64 (0.41–1.02)
 West 8.5 0.79 (0.49–1.26)
Teaching status
 Non-teaching 7.3 0.87 Ref
 Teaching 7.2 0.91 (0.65–1.27)
Location
 Rural 6.8 0.72 Ref
 Urban 7.3 1.00 (0.55–1.81)
Abbreviations: OR, odds ratio; CI, confidence interval
aStudent’s t-test used to compare means; Pearson’s χ2 test used to compare proportions.
b
Based on a logistic regression model adjusting for all variables in the table
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Table 3
Characteristics of Cirrhotic Patients Who Received a Paracentesis, Early versus Delayed
≤ 1 Day After Admission (n = 6,479) > 1 Day After Admission (n = 3,340) p-valuea
Age in years, mean (95% CI) 57.2 (56.4–58.1) 58.9 (58.0–59.9) 0.005
 < 55, % 44.1 40.6 0.04
 55–64, % 31.1 29.0
 ≥ 65, % 24.7 30.5
Male, % 67.4 58.8 <0.001
Race/ethnicity
 White, % 66.3 64.9 0.48
 Black, % 9.4 11.7
 Hispanic, % 18.0 17.2
 Other, % 6.3 6.2
Weekend admission, % 19.4 28.7 <0.001
Elective admission, % 6.7 6.9 0.88
Primary payer
 Medicare, % 35.4 45.1 0.003
 Medicaid, % 26.3 22.1
 Private, % 23.9 22.5
 Self-pay, % 9.9 7.5
 Other, % 4.5 2.8
Median zip code income
 1st quartile, % 27.6 27.5 0.30
 2nd quartile, % 25.0 28.1
 3rd quartile, % 26.6 22.8
 4th quartile, % 20.8 21.7
Elixhauser index, mean (95% CI) 3.4 (3.3–3.5) 4.0 (3.8–4.1) <0.001
Sepsis, % 8.2 9.4 0.36
Acute renal failure, % 26.2 35.1 <0.001
Hospital size
 Small, % 10.1 7.6 0.16
 Medium, % 27.1 24.7
 Large, % 62.8 67.7
Ownership/control
 Government, non-federal, % 18.3 12.2 0.016
 Private, non-profit, % 66.6 73.8
 Private, investor-owned, % 15.0 14.1
Hospital region
 Northeast, % 19.4 22.1 0.09
 Midwest, % 14.7 17.9
 South, % 35.7 35.7
 West, % 30.2 24.3
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≤ 1 Day After Admission (n = 6,479) > 1 Day After Admission (n = 3,340) p-valuea
Teaching hospital, % 54.2 48.4 0.046
Rural (vs. urban) location, % 9.9 7.9 0.17
Abbreviations: CI, confidence interval.
aStudent’s t-test used to compare means; Pearson’s χ2 test used to compare proportions.
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